Hospital-acquired, laboratory-confirmed bloodstream infection: Increased hospital stay and direct costs


Orsi, GB; di Stefano, L; Noah, N; (2002) Hospital-acquired, laboratory-confirmed bloodstream infection: Increased hospital stay and direct costs. Infection control and hospital epidemiology, 23 (4). pp. 190-7. ISSN 0899-823X DOI: https://doi.org/10.1086/502034

[img]
Preview
Text - Published Version
License: Copyright the publishers

Download (140kB) | Preview

Abstract

OBJECTIVES: To determine increased hospital stay and direct costs attributable to hospital-acquired, laboratory-confirmed bloodstream infection (BSI), and to evaluate the matching variable length of stay (LOS). DESIGN: Retrospective (historical) cohort study with 1:2 matching in intensive care units and surgical wards. SETTING: A 2,000-bed university hospital in Rome, Italy. PATIENTS: All patients admitted between January 1994 and June 1995 who had hospital-acquired, laboratory-confirmed BSI were considered cases; all others were eligible as controls. METHODS: Two controls (A and B) were selected per case in a stepwise fashion. Controls in group A were selected according to the following six criteria: ward, gender, age, diagnosis, central venous catheter, and LOS equal to the interval from admission to infection in a matched case +/- 20% (LOS +/- 20%). Controls in group B were selected according to the first five criteria, but excluded LOS +/- 20%. RESULTS: One hundred five of 108 patients were each matched with two controls. The matching appropriateness score was greater than 90%. With the use of controls in groups A and B, the case-fatality rates attributable to hospital-acquired, laboratory-confirmed BSI were 35.2% and 40.9%, respectively; the estimated risk ratios for death were 2.60 and 3.52 (P = .0001), respectively. The increased hospital stay per case attributable to hospital-acquired, laboratory-confirmed BSI was 19.1 (mean) and 13.0 (median) days for matched pairs in control group A and 19.9 (mean) and 15.0 (median) days for matched pairs in control group B. With controls in group A, the cost of increased hospital stay per patient attributable to hospital-acquired, laboratory-confirmed BSI was Euro 15,413. The additional cost per patient due to treatment was Euro 943, making the overall direct cost Euro 16,356 per case. CONCLUSIONS: This study should make it possible to estimate the cost of hospital-acquired, laboratory-confirmed BSI in most hospitals after adjusting for incidence rate. It also confirmed the use of LOS +/- 20% as a matching variable to limit overestimation of increased hospital stay. To our knowledge, this is among the first such studies in Europe.

Item Type: Article
Keywords: Blood-stream infections, critically ill patients, nosocomial, infections, attributable mortality, excess length, extra costs, bacteremia, unit, surveillance, prolongation, Bacteremia, economics, epidemiology, Cohort Studies, Cross Infection, economics, epidemiology, Health Services Research, Hospital Costs, statistics & numerical data, Hospitals, University, economics, utilization, Human, Italy, epidemiology, Length of Stay, statistics & numerical data, Retrospective Studies
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
PubMed ID: 12002233
Web of Science ID: 175006600005
URI: http://researchonline.lshtm.ac.uk/id/eprint/17643

Statistics


Download activity - last 12 months
Downloads since deposit
386Downloads
326Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item